Maze Therapeutics (NASDAQ:MAZE) Shares Break Above 200-Day Moving Average - Time to Sell?

Maze Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Maze shares moved above their 200-day moving average of $31.89, reaching $32.48 and last trading at $32.25; the stock was reported up 6.2%.
  • Analyst views are mostly positive: the consensus rating is “Buy,” with an average price target of $64.45, though one analyst rates the stock “Sell.”
  • Company insiders sold 192,991 shares worth about $5.19 million over the past 90 days. Maze reported a quarterly loss of $0.76 per share, matching analyst expectations.
  • Five stocks we like better than Maze Therapeutics.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $31.89 and traded as high as $32.48. Maze Therapeutics shares last traded at $32.25, with a volume of 488,818 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MAZE shares. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Wedbush reiterated an "outperform" rating and set a $48.00 price target on shares of Maze Therapeutics in a report on Wednesday, September 23rd. Citigroup assumed coverage on shares of Maze Therapeutics in a report on Wednesday, September 23rd. They set a "buy" rating and a $50.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and set a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $64.45.

View Our Latest Report on Maze Therapeutics

Maze Therapeutics Trading Up 6.2%

The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a fifty day simple moving average of $27.56 and a two-hundred day simple moving average of $31.89. The firm has a market cap of $1.79 billion, a PE ratio of -12.80 and a beta of 2.04.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.76). Equities analysts forecast that Maze Therapeutics, Inc. will post -2.70 EPS for the current year.

Insider Activity at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the firm's stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $32.07, for a total value of $240,525.00. Following the completion of the sale, the insider directly owned 32,316 shares of the company's stock, valued at approximately $1,036,374.12. This trade represents a 18.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,141 shares of Maze Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $26.93, for a total transaction of $434,677.13. Following the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at $434,677.13. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 192,991 shares of company stock worth $5,187,559. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Several large investors have recently bought and sold shares of the company. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC bought a new position in Maze Therapeutics in the second quarter worth $122,983,582. BlackRock Inc. purchased a new position in Maze Therapeutics during the second quarter valued at $104,525,000. Jupiter Topco LLC purchased a new position in Maze Therapeutics during the second quarter valued at $101,764,000. Finally, Alphabet Inc. bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $41,435,000.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze's pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Maze Therapeutics Right Now?

Before you consider Maze Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.

While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines